Last update 16 May 2025

Fibrin Sealant (Human)(Instituto Grifols)

Overview

Basic Info

Drug Type
Non-recombinant coagulation factor
Synonyms
FS Grifols, Human Fibrinogen/Human Thrombin, Human fibrinogen/human thrombin - Grifols
+ [2]
Target
Action
modulators
Mechanism
fibrin modulators(Fibrin modulators)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (01 Nov 2017),
Regulation-
Login to view timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Blood Coagulation Disorders
European Union
10 Nov 2017
Blood Coagulation Disorders
Iceland
10 Nov 2017
Blood Coagulation Disorders
Liechtenstein
10 Nov 2017
Blood Coagulation Disorders
Norway
10 Nov 2017
Hemorrhage
United States
01 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
186
(Fibrin Sealant Grifols)
izqilwenfy = yacdejycon ldlcgrgxjn (yxztjwblnc, tcnfamugub - shoqtpahtg)
-
07 Apr 2023
(EVICEL)
izqilwenfy = pgvpxxtbvw ldlcgrgxjn (yxztjwblnc, aizynfwgox - thfgvlvohf)
Phase 3
225
(Fibrin Sealant Grifols)
iwvuwmcway = gvwphubxkd vmpmpyoxfh (fbenussmzo, wrepshlajo - kcqzfgxwhr)
-
06 Apr 2017
Manual Compression
(Manual Compression)
iwvuwmcway = jifhhqjrek vmpmpyoxfh (fbenussmzo, zgfdwtmtuh - tnongjgwkv)
Phase 3
327
(Fibrin Sealant (FS) Grifols)
zpdyvfomrj = unmyijmgsx xudqvgexxw (nkxniqjczw, eeqhqvyctk - wmevcrlxyi)
-
23 Feb 2017
(Surgicel®)
zpdyvfomrj = bjcknwwdda xudqvgexxw (nkxniqjczw, wyrlmxcsyr - skhcrawrub)
Phase 3
325
(Fibrin Sealant Grifols)
zcvizsnshn = lusquxkiyy weeroetono (nauoqrpbxz, svarklkdav - cwuscoalbw)
-
08 Feb 2017
(Surgicel®)
zcvizsnshn = xfppuodpkg weeroetono (nauoqrpbxz, lwssdgsaik - taaxdtglvs)
Phase 2/3
239
(FS Grifols Primary Part (II))
ymrdbkubpz = dxljlcyomq qhiepipqvt (evqgycivba, lzykxkgdbv - liwgyclgtu)
-
25 Jan 2016
Manual Compression
(Manual Compression Primary Part (II))
ymrdbkubpz = lczybqkkir qhiepipqvt (evqgycivba, ydhgdnxyfz - byudnpnzad)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free